ETBX-061
Clinical Trials Overview
2 trials found
About ETBX-061
Etbx-061 is a multi-targeted recombinant adenovirus type 5 (Ad5) based cancer vaccine that targets three tumor-associated antigens: CEA (carcinoembryonic antigen), MUC1 (mucin 1), and brachyury. This immunotherapeutic agent is designed to stimulate the immune system to recognize and attack colorectal cancer cells expressing these specific antigens. The vaccine is part of combination immunotherapy regimens aimed at generating robust anti-tumor immune responses in patients with advanced colorectal cancer.
Category
Other Medications
Brand Name
Not yet branded
Mechanism
Etbx-061 utilizes a replication-defective adenovirus vector to deliver genetic material encoding CEA, MUC1, and brachyury antigens directly to immune cells. Upon administration, the vaccine promotes the presentation of these tumor-associated antigens to T-cells, triggering both cellular and humoral immune responses. This multi-antigen approach aims to overcome tumor immune evasion by targeting multiple pathways simultaneously and reducing the likelihood of antigen loss variants.
2
Total Trials
0
Recruiting
0
Active
2
Completed
13
Total Enrollment
1
Countries
NCT03563157
Phase 1
Completed
2 patients
Medications:
5-Fluorouracil
ALT-803
Avelumab
Capecitabine
Cetuximab
Cyclophosphamide
ETBX-011
ETBX-021
ETBX-051
ETBX-061
GI-4000
GI-6207
GI-6301
Hank
Leucovorin
Nab-Paclitaxel
Oxaliplatin
Regorafenib
QUILT 3.071 NANT Colorectal Cancer (CRC) Vaccine: This is a Phase 1b/2 study investigating the effect of NANT CRC vaccine vs regorafenib in subjects with CRC who were previously treated with SOC.
United States
NCT03384316
Phase 1
Completed
11 patients
Background:
ETBX-011, ETBX-061, and ETBX-051 are cancer vaccines. Their goal is to teach the immune system to target and kill cancer cells. The vaccines target 3 proteins found in many types of cancer. Researchers think targeting all 3 proteins in u...
United States